Actualités Cipher Pharmaceuticals Inc - CPH | Actions Toronto Stock Exchange

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Notice of Cipher Pharmaceuticals Inc. Q2 2016 Conference Call

Notice of Cipher Pharmaceuticals Inc. Q2 2016 Conference Call PR Newswire MISSISSAUGA, ON, July 20, 2016 MISSISSAUGA, ON, July 20, 2016...

Cipher Pharmaceuticals announces Ozenoxacin accepted for review by Health Canada

Cipher Pharmaceuticals announces Ozenoxacin accepted for review by Health Canada PR Newswire MISSISSAUGA, ON, July 12, 2016 MISSISSAUGA, ON, July...

Special Committee of Cipher Pharmaceuticals Responds to Early Warning Report Filed by 1207407 Ontario Limited

Special Committee of Cipher Pharmaceuticals Responds to Early Warning Report Filed by 1207407 Ontario Limited PR Newswire MISSISSAUGA, ON, July...

Cipher Pharmaceuticals Out-Licenses Rights to ASF-1096 for Anorectal Disorders

Cipher Pharmaceuticals Out-Licenses Rights to ASF-1096 for Anorectal Disorders PR Newswire MISSISSAUGA, ON, June 20, 2016 MISSISSAUGA, ON, June...

Cipher Pharmaceuticals to Present at Two Upcoming U.S. Investor Conferences

Cipher Pharmaceuticals to Present at Two Upcoming U.S. Investor Conferences PR Newswire MISSISSAUGA, ON, May 31, 2016 MISSISSAUGA, ON, May 31...

Cipher Pharmaceuticals Reports Voting Results from Annual and Special Meeting of Shareholders

Cipher Pharmaceuticals Reports Voting Results from Annual and Special Meeting of Shareholders PR Newswire MISSISSAUGA, ON, May 6, 2016...

Cipher Pharmaceuticals Reports Q1 2016 Financial Results

Cipher Pharmaceuticals Reports Q1 2016 Financial Results PR Newswire MISSISSAUGA, ON, May 5, 2016 - Revenue increased 23%- Delivered on...

Cipher Pharmaceuticals Acquires Worldwide Rights to Dalhousie University's Investigational Tattoo Removal Cream

Cipher Pharmaceuticals Acquires Worldwide Rights to Dalhousie University's Investigational Tattoo Removal Cream PR Newswire MISSISSAUGA, ON...

Notice of Cipher Pharmaceuticals Q1 2016 Conference Call & Annual and Special Meeting

Notice of Cipher Pharmaceuticals Q1 2016 Conference Call & Annual and Special Meeting PR Newswire MISSISSAUGA, ON, April 22, 2016...

Cipher Pharmaceuticals Announces Retirement of CFO Norm Evans

Cipher Pharmaceuticals Announces Retirement of CFO Norm Evans PR Newswire MISSISSAUGA, ON, April 22, 2016 MISSISSAUGA, ON, April 22, 2016...

Cipher Pharmaceuticals Proposes Adding Rosemary A. Crane and Dr. Renee P. Tannenbaum To Board of Directors

Cipher Pharmaceuticals Proposes Adding Rosemary A. Crane and Dr. Renee P. Tannenbaum To Board of Directors PR Newswire MISSISSAUGA, ON, April 7...

Cipher Pharmaceuticals Announces Approvals of Astion Acquired Barrier Creams by Health Canada and the Medicines Evaluation Bo...

Cipher Pharmaceuticals Announces Approvals of Astion Acquired Barrier Creams by Health Canada and the Medicines Evaluation Board PR...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Cipher Pharmaceuticals Inc (CPH)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

CPH Actualités

Notice of Cipher Pharmaceuticals Inc. Q2 2016 Conference Call

Cipher Pharmaceuticals announces Ozenoxacin accepted for review by Health Canada

Special Committee of Cipher Pharmaceuticals Responds to Early Warning Report Filed by 1207407 Ontario Limited

Cipher Pharmaceuticals Out-Licenses Rights to ASF-1096 for Anorectal Disorders

Cipher Pharmaceuticals to Present at Two Upcoming U.S. Investor Conferences

Cipher Pharmaceuticals Reports Voting Results from Annual and Special Meeting of Shareholders

Cipher Pharmaceuticals Reports Q1 2016 Financial Results

Cipher Pharmaceuticals Acquires Worldwide Rights to Dalhousie University's Investigational Tattoo Removal Cream

Notice of Cipher Pharmaceuticals Q1 2016 Conference Call & Annual and Special Meeting

Cipher Pharmaceuticals Announces Retirement of CFO Norm Evans

Cipher Pharmaceuticals Proposes Adding Rosemary A. Crane and Dr. Renee P. Tannenbaum To Board of Directors

Cipher Pharmaceuticals Announces Approvals of Astion Acquired Barrier Creams by Health Canada and the Medicines Evaluation Bo...

Cipher Pharmaceuticals announces Canadian launch of Beteflam™

Cipher Pharmaceuticals Appoints Ralph Bohrer President & General Manager of U.S. Business

Cipher Pharmaceuticals to Present at Two Upcoming Investor Conferences

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Cipher Pharmaceuticals Inc (CPH) Actualités

Cipher Pharmaceuticals Inc (CPH)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

CPH Actualités

Notice of Cipher Pharmaceuticals Inc. Q2 2016 Conference Call

Cipher Pharmaceuticals announces Ozenoxacin accepted for review by Health Canada

Special Committee of Cipher Pharmaceuticals Responds to Early Warning Report Filed by 1207407 Ontario Limited

Cipher Pharmaceuticals Out-Licenses Rights to ASF-1096 for Anorectal Disorders

Cipher Pharmaceuticals to Present at Two Upcoming U.S. Investor Conferences

Cipher Pharmaceuticals Reports Voting Results from Annual and Special Meeting of Shareholders

Cipher Pharmaceuticals Reports Q1 2016 Financial Results

Cipher Pharmaceuticals Acquires Worldwide Rights to Dalhousie University's Investigational Tattoo Removal Cream

Notice of Cipher Pharmaceuticals Q1 2016 Conference Call & Annual and Special Meeting

Cipher Pharmaceuticals Announces Retirement of CFO Norm Evans

Cipher Pharmaceuticals Proposes Adding Rosemary A. Crane and Dr. Renee P. Tannenbaum To Board of Directors

Cipher Pharmaceuticals Announces Approvals of Astion Acquired Barrier Creams by Health Canada and the Medicines Evaluation Bo...

Cipher Pharmaceuticals announces Canadian launch of Beteflam™

Cipher Pharmaceuticals Appoints Ralph Bohrer President & General Manager of U.S. Business

Cipher Pharmaceuticals to Present at Two Upcoming Investor Conferences

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application